000915Wit DyneSZSE

Shandong Wit Dyne Health Co., Ltd.

华特达因

000915

Shenzhen Stock Exchange

BoardMain Board of Shenzhen Stock Exchange
IndustryPharmaceutical Manufacturing
ISINCNE000000Z28
ListedJune 9, 1999
Websitewww.sd-wit.com
IR Emailwit@sd-wit.com
Phone(+86)531-85198606
Sourcecninfo.com.cn
AddressHuate Square, No. 17703, Jingshi Road, Jinan, Shandong

Company Overview

Shandong Wit Dyne Health Co., Ltd. is a pharmaceutical manufacturing company listed on the Shenzhen Stock Exchange since 1999. The company specializes in the development, production, and marketing of children's medicines, foods, and commodities through its controlling subsidiary, Shandong Dyne Marine Biopharmaceutical Co., Ltd. Dyne Pharm, as it is commonly known, focuses on products that cater to children's health, including well-known items such as Vitamin AD drops and compound calcium carbonate effervescent particles. Dyne Pharm operates a modern manufacturing facility in Rongcheng City, Shandong Province, equipped with advanced production lines that meet international GMP standards. The company emphasizes research and development, supported by its Beijing DYNE High-tech Pediatric Pharmaceutical R&D Institute and DYNE Rongcheng technology R&D center, which foster innovation in children's drug formulations. Dyne Pharm has established a strong marketing presence, adapting its strategies to align with national policies and market dynamics, thereby enhancing its brand reputation and market position in the children's healthcare sector.

AI-generated from company disclosures and CNInfo data.

Company Profile

DYNE Pharma focuses on the cause of children's health, adheres to the strategic goal of "becoming the leader enterprise in the field of children's health care and treatment", adheres to the professionalism, and continues to promote the industrial layout in the field of children's health. Beijing DYNE High-tech Pediatric Pharmaceutical R&D Institute and DYNE Rongcheng technology R & D center have a group of high-level children's drug R & D and technological innovation talents. Guided by children's drugs demand, we carry out new products R & D and the pivotal technological innovation, constantly enrich the children's drug series and improve the children's drugs layout. DYNE pharma has built a modern manufacturing base with high standards and fully meeting the GMP requirements in Rongcheng, Shandong. Soft capsule workshops have obtained Australian quality certification, and the quality in production review is in line with international standards. DYNE pharma has built an excellent marketing team, we insist in promoting the academic professionally, and continuously innovated the marketing mode according to the changes of national policies and markets. The precise core marketing strategy has formed a solid brand barrier and market foundation, and the credibility and reputation of DYNE pharma in the market have been continuously improved.

30 announcements tracked· Last: June 22, 2026

Key Financials

Revenue¥412.3M
Net Profit¥110.6M
ROE3.72%
Debt Ratio7.95%
Monetary Funds¥2.06bn
Receivables¥119.3M
Goodwill¥26.1M
Total Shares234.3M

Announcements

30 totalCSV

Notes & Comments

Sign in to leave a comment or private note.

No notes or comments yet.